Pfizer Inc. PFE, +0.99% and German partner BioNTEch SE BNTX, -0.57% announced positive results from a Phase 1/2 trial of their combined mRNA flu/COVID vaccine on Thursday in adults aged 18 to 64. The vaccine candidates were compared to a licensed influenza vaccine and the companies’ omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine given at the same visit.
“The data from the trial showed that the companies’ lead formulations demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains,” the companies said in a joint statement. The companies plan to start a Phase 3 trial in the coming months.
Source: Law Daily Report (lawdailyreport.net)
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Kimberly-Clark posts better -than-expected profit but sales fall slightly shortCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Source: MarketWatch - 🏆 3. / 97 Read more »
AstraZeneca said U.S. FDA has accepted for review its Flumist self-administered flu vaccineCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Source: MarketWatch - 🏆 3. / 97 Read more »
Stellantis and Orano to enter joint venture for recycling EV batteries and scrap from gigafactoriesCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Source: MarketWatch - 🏆 3. / 97 Read more »
Overstock to rename itself Beyond Inc. from Nov. 6 and switch listing to NYSE under new ticker ‘BYON’Ciara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Source: MarketWatch - 🏆 3. / 97 Read more »
Teladoc’s stock tumbles after-hours after company misses sales estimates and offers soft guidanceCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Source: MarketWatch - 🏆 3. / 97 Read more »
Usana Health’s stock dips then turns flat after earnings miss and lowered guidanceCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Source: MarketWatch - 🏆 3. / 97 Read more »